TERUMO CORP

Terumo Corp’s strategic shift into cell‑therapy and safe IV bags boosts margins, cuts costs, and meets new regulatory demands—fueling growth and patient‑safety gains.

Terumo Corp’s 3% share dip amid a Japanese market rally reflects sector rotation, not weak fundamentals—its strong margins, R&D focus and AI‑driven device innovation keep investors confident in its value‑based growth strategy.

Terumo Corp’s share price jumps amid a Japanese market sell‑off, showing medical‑device resilience and investor confidence in Japan’s aging‑population sector.

Terumo Corporation forecasts robust FY 2027 earnings and revenue growth, with higher dividends, driven by global demand and a strong U.S./Europe focus.

Terumo Corporation maintains a steady position amid rising global demand for advanced medical devices, leveraging a diversified portfolio, strong distribution network, and robust R&D to capture growth in key segments while staying compliant and …

Terumo Corporation reports modest Q4 2026 revenue growth, slight EPS dip, and strong transfusion/infusion sales—positioning it to capture rising peripheral vascular device demand.

Terumo’s diversified vascular, surgical and dialysis portfolio positions the Japanese company to capture Japan’s rapidly growing high‑margin medical‑device market, offering investors a strong growth‑driven opportunity.

Terumo’s dominance in Japan’s growing surgical, blood‑banking, dialysis, and cardiac device markets—backed by rigorous compliance, cutting‑edge tech, and proven clinical outcomes—offers clinicians superior efficiency and patient care.

Terumo Corp. partners with Santersus AG to launch a high‑yield apheresis device that could cut ICU stays and lower sepsis mortality while meeting global reimbursement and cost‑effectiveness goals.

Terumo’s new precision flow‑control IV tubing offers 0.1 mL/min accuracy, cutting infusion drift by 15% and positioning the company as a hidden leader in ICU infusion tech.